2 The technology

Aflibercept (Eylea, Bayer)

Marketing authorisation

Aflibercept has a UK marketing authorisation for 'treating visual impairment due to myopic choroidal neovascularisation in adults'.

Recommended dose and schedule

The recommended dose is a single intravitreal injection of 2 mg aflibercept (equivalent to 50 microlitres).

Extra doses may be used if visual or anatomic outcomes indicate that the disease persists. Recurrences should be treated as a new manifestation of the disease. For full details, see the summary of product characteristics.


The list price of aflibercept 40 mg/mL is £816 per 0.1‑mL vial (excluding VAT; British national formulary [BNF] online [accessed July 2017]).

The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of aflibercept, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS.

  • National Institute for Health and Care Excellence (NICE)